Display Settings:

Format

Send to:

Choose Destination
    Biochim Biophys Acta. 2001 Aug 31;1551(1):M11-8.

    Bcr-Abl inhibition as a modality of CML therapeutics.

    Source

    Novartis Pharma AG, Research Oncology, Basel, Switzerland.

    PMID:
    11553417
    [PubMed - indexed for MEDLINE]

      Supplemental Content

      Icon for Elsevier Science

      Save items

      loading

      Recent activity

      Your browsing activity is empty.

      Activity recording is turned off.

      Turn recording back on

      See more...
      Write to the Help Desk